Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics (NQ: RVNC )

33.13 -0.75 (-2.21%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 728,841
Open 33.37
Bid (Size) 31.75 (1)
Ask (Size) 34.24 (1)
Prev. Close 33.88
Today's Range 32.88 - 33.98
52wk Range 11.27 - 34.55
Shares Outstanding 71,829,718
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
What 4 Analyst Ratings Have To Say About Revance Therapeutics
 
Via Benzinga
Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook
Evolus Inc (NASDAQ: EOLS) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively. 
Via Benzinga

Performance

YTD
+80.45%
+80.45%
1 Month
+77.93%
+77.93%
3 Month
+48.50%
+48.50%
6 Month
+111.56%
+111.56%
1 Year
+163.98%
+163.98%

More News

Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Tesla, Apple, Nuwellis, Revance, Lululemon: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday
Via Benzinga
Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results
From Revance Therapeutics, Inc.
Via Business Wire
Macy's, Acuity Brands And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
Via FinancialNewsMedia
Exposures COVID-19
What 8 Analyst Ratings Have To Say About Revance Therapeutics
Via Benzinga
Revance to Participate in the Stifel 2022 Healthcare Conference
From Revance Therapeutics, Inc.
Via Business Wire
Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance Therapeutics's Earnings: A Preview
Via Benzinga
Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
From Revance Therapeutics, Inc.
Via Business Wire
Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
From Revance Therapeutics, Inc.
Via Business Wire
Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer
From Revance Therapeutics, Inc.
Via Business Wire
What 7 Analyst Ratings Have To Say About Revance Therapeutics
Via Benzinga
Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
From Revance Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Via Benzinga
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
Via MarketBeat
Topics Stocks
Exposures US Equities
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.